BAFNAPHARM

BAFNAPHARM: Members of the Exchange are hereby informed that the trading in Equity Shares of Bafna Pharmaceuticals Limited shall be suspended w.e.f. August 26, 2019 (i.e. closing hours of trading on August 23, 2019) on account of Reduction of Share Capital.

The Exchange had sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated regarding Disclosure pursuant to Regulation 30 of SEBI ( Listing Obligations and Disclosure Requirements) Regulations, 2015.On basis of above the Company is required to clarify following:1. Any other material information not involving commercial secrets2. Salient features, not involving commercial secrets, of the resolution plan approved by the Tribunal, in such form as may be specified3. Approval of resolution plan by the Tribunal or rejection, if applicable4. Filing of resolution plan

BAFNAPHARM:The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 18-Jul-2018, regarding " Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Disclosure pursuant to Regulation 30 of SEBI ( Listing Obligations and Disclosure Requirements) Regulations, 2015.'.". On basis of above the Company is required to clarify following: 1. Any other material information not involving commercial secrets<br> 2. Salient features, not involving commercial secrets, of the resolution plan approved by the Tribunal, in such form as may be specifi

The Exchange had sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 06-Oct-2017, regarding "Outcome of Board Meeting held on October 06, 2017.". On basis of above the Company is required to clarify following: 1. Disclosure of relationships between directors (in case of appointment of a director).2. Brief profile (in case of appointment);The response of the Company is attached.

BAFNAPHARM:The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 06-Oct-2017, regarding "Outcome of Board Meeting held on October 06, 2017.". On basis of above the Company is required to clarify following: 1. Disclosure of relationships between directors (in case of appointment of a director).2. Brief profile (in case of appointment);The response of the Company is awaited.

BAFNAPHARM:The Exchange had sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 12-Sep-2017, regarding " Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 08, 2017". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is attached.

BAFNAPHARM:The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 12-Sep-2017, regarding " Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 08, 2017". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.

BAFNAPHARM:The Exchange had sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 08-Aug-2017, regarding " Outcome of Board Meeting held on August 08, 2017.On basis of above the Company is required to clarify following: 1. Date of appointment/cessation (as applicable) & term of appointment;The response of the Company is enclosed.

BAFNAPHARM:The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 08-Aug-2017, regarding " Outcome of Board Meeting held on August 08, 2017.On basis of above the Company is required to clarify following: 1. Date of appointment/cessation (as applicable) & term of appointment;The response of the Company is awaited.

BAFNAPHARM: The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 09-Jan-2017, informing that the Board of Directors of the Company was held on January 07, 2017, In the meeting, the following matters were decided by the Board: Considered and decided to issue 80,00,000 share warrants on preferential basis to promoter and non-promoter group at such price as may be arrived at in accordance with SEBI (ICDR) Regulations, 2009, subject to the approval of the members of the Company through Postal Ballot by way of passing a special resolution under

BAFNAPHARM:The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 09-Jan-2017, informing that the Board of Directors of the Company was held on January 07, 2017, In the meeting, the following matters were decided by the Board: Considered and decided to issue 80,00,000 share warrants on preferential basis to promoter and non-promoter group at such price as may be arrived at in accordance with SEBI (ICDR) Regulations, 2009, subject to the approval of the members of the Company through Postal Ballot by way of passing a special resolution under

The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 05-Jan-2017, regarding "Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company was held on January 04, 2017, where it was decided to withdraw entire preferential issue of 40,00,000 share warrants and in-principle application filed with the Stock Exchanges.On basis of above the Company is required to clarify following:1. Reasons for cancellation of the same.The response of the Company is enclosed.

BAFNAPHARM:The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 05-Jan-2017, regarding "Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company was held on January 04, 2017, where it was decided to withdraw entire preferential issue of 40,00,000 share warrants and in-principle application filed with the Stock Exchanges.On basis of above the Company is required to clarify following:1. Reasons for cancellation of the same.The response of the Company is awaited.

BAFNAPHARM:The Exchange had sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 11-Nov-2016, regarding the Outcome of Board Meeting held on 11th November, 2016.On basis of above the Company was required to clarify following:1. Brief profile (in case of appointment);The response of the Company is attached.

BAFNAPHARM:The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 11-Nov-2016, regarding "Bafna Pharmaceuticals Limited has informed the Exchange the Outcome of Board Meeting held on 11th November, 2016".On basis of above the Company is required to clarify following:1. Brief profile (in case of appointment);The response of the Company is awaited.

News Verification : The media had reports that " US based generic drug maker Mylan and two Indian Pharma Cos are in race to accquire Bafna Pharmaceuticals Ltd" . The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Bafna Pharmaceuticals Limited has vide its letter inter-alia stated, "We wish to clarify that the news report appearing in the section of media regarding Bafna Pharma are speculative. The Company has a policy of desisting to